The rapid diagnosis of sensitivity or resistance to dopamine agonists with depot bromocriptine.
Some patients with hyperprolactinaemia are unable to tolerate even low doses of oral bromocriptine. In such cases, it is difficult to predict whether serum prolactin might be normalized if higher doses could be tolerated, or whether true resistance to bromocriptine is present. We have investigated 8...
Principais autores: | Grossman, A, Wass, J, Besser, M |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
1987
|
Registros relacionados
-
Depot-bromocriptine treatment for prolactinomas and acromegaly.
por: Grossman, A, et al.
Publicado em: (1986) -
DEPOT BROMOCRIPTINE IN THE TREATMENT OF PROLACTINOMAS AND ACROMEGALY
por: Grossman, A, et al.
Publicado em: (1985) -
Terguride--a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine.
por: Ciccarelli, E, et al.
Publicado em: (1988) -
Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study.
por: Verhelst, J, et al.
Publicado em: (1991) -
Oral prednisolone supplement abolishes the acute adverse effects following initiation of depot bromocriptine therapy.
por: Jenkins, P, et al.
Publicado em: (1996)